Shanghai medicine: parecoxib sodium for injection approved for production

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Sino Biopharm and Boehringer Ingelheim Sign Option and License Deal for Six Cancer Programs

Sino Biopharmaceutical（中国生物制药）and Boehringer Ingelheim（勃林格殷格翰）announced an option and license agreement on November 4 covering six preclinical cancer programs. Sino Biopharm will receive USD 358 million in upfront and near-term payments and may receive up to USD 7 billion in additional option, development, regulatory and commercial milestone payments.

Wantai Launches Nine-Valent HPV Vaccine Cecolin 9 in Thailand

Wantai Biological（万泰生物）said on November 2 that its nine-valent HPV vaccine, Cecolin 9（馨可宁9）, had launched in Thailand. The product was jointly developed by its subsidiary Xiamen Innovax Biotech（厦门万泰沧海生物技术有限公司）and Xiamen University（厦门大学）.

Futurtec Adds CE MDR-Certified Knee-Replacement System to Its Orthopedic Robotics Portfolio

Futurtec（鑫君特）has received European Union Medical Device Regulation certification for its ORTHBOT X knee-replacement surgical navigation and positioning system, according to a company announcement reported by MedChina in August.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).